Menu

EMAIL ajc1020@medschl.cam.ac.uk
Department
  • Clinical Neurosciences
    • School
  • Clinical Medicine
    • Institute
  • Neurology Unit
  • MS Society Cambridge Centre for Myelin Repair
    • Click to view home page
    Research Theme Beyond the Neuron Lifelong Brain Development and Brain Ageing
    Research Focus

    Keywords

  • Neuroimmunology
  • Neurodegeneration
  • CNS Repair
  • Remyelination

    • Clinical Conditions

  • Psychotic disorders
  • Multiple sclerosis

    • Equipment & Techniques

  • Randomised control trials
  • Electrophysiological recording techniques

    • Back

    Professor Alasdair Coles

    University Position
    Professor
    Head of Department
    Professor Alasdair Coles is pleased to consider applications from prospective PhD students.

    Interests

    We study people with immunological illnesses of the brain, especially multiple sclerosis. Our most important work to date has been on alemtuzumab (Campath-1H), a humanised monoclonal antibody made originally in Cambridge. We started using it to treat multiple sclerosis in1991. In September 2013, alemtuzumab received its European license and in 2014 it was approved by the FDA and by NICE. Our focus now is on remyelinating therapies. We have completed our first such trial ("CCMROne") of bexarotene, publishing our results in 2021. We are completing CCMR Two , testing metformin and clemastine. And we have plans for CCMR Three. We are also doing a study of immunotherapy in people with psychosis associated with anti-neuronal antibodies. Alasdair is Deputy Head of Department for Clinical Neuroscience and also Co-Director of the Cambridge Centre for Myelin Repair.

    Remyelination in multiple sclerosis

    Bexarotene improves conduction in demyelinated visual pathways in multiple sclerosis [Brown, Lancet Neurology 2021]

    Collaborators

    Cambridge
  • Stephen Sawcer
  • Will Brown
  • Nick Cunniffe
  • David Menon
  • Peter Jones
  • Joanne Jones

    • Associated News Items

    Key Publications

    Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial.

    DOI: http://doi.org/10.1177/13524585241233177
    Journal: Multiple Sclerosis Journal
    E-pub date: 1 Jul 2024
    Authors: CE McMurran, T Mukherjee, JWL Brown, AJ Coles, NG Cunniffe

    Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

    DOI: http://doi.org/10.1177/17562864231194823
    Journal: Ther Adv Neurol Disord
    E-pub date: 1 Aug 2023
    Authors: AJ Coles, A Achiron, A Traboulsee, BA Singer, C Pozzilli, C Oreja-Guevara, G Giovannoni, G Comi, MS Freedman, T Ziemssen, D Shiota, AM Rawlings, AT Wong, M Chirieac, X Montalban

    Remyelination varies between and within lesions in multiple sclerosis following bexarotene.

    DOI: http://doi.org/10.1002/acn3.51662
    Journal: Ann Clin Transl Neurol
    E-pub date: 1 Oct 2022
    Authors: JWL Brown, F Prados, DR Altmann, B Kanber, J Stutters, NG Cunniffe, JL Jones, ZG Georgieva, EJ Needham, C Daruwalla, CG Wheeler-Kingshott, P Connick, S Chandran, R Franklin, D MacManus, R Samson, A Coles, D Chard

    Remyelination in humans due to a retinoid-X receptor agonist is age-dependent.

    DOI: http://doi.org/10.1002/acn3.51595
    Journal: Ann Clin Transl Neurol
    E-pub date: 1 Jul 2022
    Authors: CE McMurran, T Mukherjee, JWL Brown, AW Michell, DT Chard, RJM Franklin, AJ Coles, NG Cunniffe

    Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.

    DOI: http://doi.org/10.1177/13524585211061335
    Journal: Mult Scler
    E-pub date: 1 Apr 2022
    Authors: AJ Coles, JL Jones, P Vermersch, A Traboulsee, AD Bass, A Boster, A Chan, G Comi, Ó Fernández, G Giovannoni, E Kubala Havrdova, C LaGanke, X Montalban, C Oreja-Guevara, F Piehl, H Wiendl, T Ziemssen

    Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.

    DOI: http://doi.org/10.1016/j.msard.2021.103458
    Journal: Mult Scler Relat Disord
    E-pub date: 1 Jan 2022
    Authors: A Garjani, S Patel, D Bharkhada, W Rashid, A Coles, GR Law, N Evangelou

    Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.

    DOI: http://doi.org/10.1016/S1474-4422(21)00179-4
    Journal: Lancet Neurol
    E-pub date: 1 Sep 2021
    Authors: JWL Brown, NG Cunniffe, F Prados, B Kanber, JL Jones, E Needham, Z Georgieva, D Rog, OR Pearson, J Overell, D MacManus, RS Samson, J Stutters, C Ffrench-Constant, CAM Gandini Wheeler-Kingshott, C Moran, PD Flynn, AW Michell, RJM Franklin, S Chandran, DR Altmann, DT Chard, P Connick, AJ Coles

    Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.

    DOI: http://doi.org/10.1177/1756286420982134
    Journal: Ther Adv Neurol Disord
    E-pub date: 1 Aug 2021
    Authors: AJ Coles, DL Arnold, AD Bass, AL Boster, DAS Compston, Ó Fernández, EK Havrdová, K Nakamura, A Traboulsee, T Ziemssen, A Jacobs, DH Margolin, X Huang, N Daizadeh, MC Chirieac, KW Selmaj

    The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro.

    DOI: http://doi.org/10.3389/fimmu.2021.712241
    Journal: Front Immunol
    E-pub date: 1 Aug 2021
    Authors: CM Gaunt, DB Rainbow, RJ Mackenzie, LB Jarvis, HS Mousa, N Cunniffe, Z Georgieva, JW Brown, AJ Coles, JL Jones

    Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.

    DOI: http://doi.org/10.1136/jnnp-2020-324286
    Journal: J Neurol Neurosurg Psychiatry
    E-pub date: 1 Mar 2021
    Authors: N Cunniffe, KA Vuong, D Ainslie, D Baker, J Beveridge, S Bickley, P Camilleri, M Craner, D Fitzgerald, AG de la Fuente, G Giovannoni, E Gray, L Hazlehurst, R Kapoor, R Kaur, D Kozlowski, B Lumicisi, D Mahad, B Neumann, A Palmer, L Peruzzotti-Jametti, S Pluchino, J Robertson, A Rothaul, L Shellard, KJ Smith, A Wilkins, A Williams, A Coles

    Promoting remyelination in multiple sclerosis.

    DOI: http://doi.org/10.1007/s00415-019-09421-x
    Journal: J Neurol
    E-pub date: 1 Jan 2021
    Authors: N Cunniffe, A Coles

    Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.

    DOI: http://doi.org/10.1007/s00415-020-09983-1
    Journal: J Neurol
    E-pub date: 1 Nov 2020
    Authors: B Steingo, Y Al Malik, AD Bass, R Berkovich, M Carraro, Ó Fernández, C Ionete, L Massacesi, SG Meuth, DD Mitsikostas, G Pardo, RF Simm, A Traboulsee, Z Choudhry, N Daizadeh, DAS Compston, CAMMS223, CAMMS03409, and TOPAZ Investigators

    Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

    DOI: http://doi.org/10.1093/brain/awaa231
    Journal: Brain
    E-pub date: 1 Sep 2020
    Authors: I Roos, E Leray, F Frascoli, R Casey, JWL Brown, D Horakova, EK Havrdova, M Trojano, F Patti, G Izquierdo, S Eichau, M Onofrj, A Lugaresi, A Prat, M Girard, P Grammond, P Sola, D Ferraro, S Ozakbas, R Bergamaschi, MJ Sá, E Cartechini, C Boz, F Granella, R Hupperts, M Terzi, J Lechner-Scott, D Spitaleri, V Van Pesch, A Soysal, J Olascoaga, J Prevost, E Aguera-Morales, M Slee, T Csepany, R Turkoglu, Y Sidhom, R Gouider, B Van Wijmeersch, P McCombe, R Macdonell, A Coles, CB Malpas, H Butzkueven, S Vukusic, T Kalincik, MSBase, OFSEP investigators

    Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.

    DOI: http://doi.org/10.1177/1352458519852093
    Journal: Mult Scler
    E-pub date: 31 Aug 2020
    Authors: JWL Brown, F Prados Carrasco, A Eshaghi, CH Sudre, T Button, M Pardini, RS Samson, S Ourselin, CAG Wheeler-Kingshott, JL Jones, AJ Coles, DT Chard

    Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

    DOI: http://doi.org/10.1016/S1474-4422(20)30067-3
    Journal: Lancet Neurol
    E-pub date: 1 Apr 2020
    Authors: A He, B Merkel, JWL Brown, L Zhovits Ryerson, I Kister, CB Malpas, S Sharmin, D Horakova, E Kubala Havrdova, T Spelman, G Izquierdo, S Eichau, M Trojano, A Lugaresi, R Hupperts, P Sola, D Ferraro, J Lycke, F Grand'Maison, A Prat, M Girard, P Duquette, C Larochelle, A Svenningsson, T Petersen, P Grammond, F Granella, V Van Pesch, R Bergamaschi, C McGuigan, A Coles, J Hillert, F Piehl, H Butzkueven, T Kalincik, MSBase study group

    Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).

    DOI: http://doi.org/10.1186/s13063-019-3336-1
    Journal: Trials
    E-pub date: 7 Jun 2019
    Authors: B Lennox, K Yeeles, PB Jones, M Zandi, E Joyce, L-M Yu, G Tomei, R Pollard, S-A Vincent, M Shimazaki, I Cairns, F Dowling, T Kabir, TRE Barnes, A Lingford Hughes, AA Hosseini, T Harrower, C Buckley, A Coles

    Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

    DOI: http://doi.org/10.1001/jama.2018.20588
    Journal: JAMA
    E-pub date: 15 Jan 2019
    Authors: JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, M Girard, P Duquette, M Trojano, A Lugaresi, R Bergamaschi, P Grammond, R Alroughani, R Hupperts, P McCombe, V Van Pesch, P Sola, D Ferraro, F Grand'Maison, M Terzi, J Lechner-Scott, S Flechter, M Slee, V Shaygannejad, E Pucci, F Granella, V Jokubaitis, M Willis, C Rice, N Scolding, A Wilkins, OR Pearson, T Ziemssen, M Hutchinson, K Harding, J Jones, C McGuigan, H Butzkueven, T Kalincik, N Robertson, MSBase Study Group

    Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.

    DOI: http://doi.org/10.1210/jc.2018-00359
    Journal: J Clin Endocrinol Metab
    E-pub date: 1 Aug 2018
    Authors: N Pariani, M Willis, I Muller, S Healy, T Nasser, A McGowan, G Lyons, J Jones, K Chatterjee, C Dayan, N Robertson, A Coles, C Moran

    Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

    DOI: http://doi.org/10.1172/jci.insight.93739
    Journal: JCI Insight
    E-pub date: 17 Aug 2017
    Authors: ML Pekalski, AR García, RC Ferreira, DB Rainbow, DJ Smyth, M Mashar, J Brady, N Savinykh, XC Dopico, S Mahmood, S Duley, HE Stevens, NM Walker, AJ Cutler, F Waldron-Lynch, DB Dunger, C Shannon-Lowe, AJ Coles, JL Jones, C Wallace, JA Todd, LS Wicker

    Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

    DOI: http://doi.org/10.1016/S1474-4422(17)30007-8
    Journal: Lancet Neurol
    E-pub date: 1 Apr 2017
    Authors: T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, A Wilkins, O Pearson, T Ziemssen, M Hutchinson, C McGuigan, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, G Izquierdo, A Lugaresi, A Prat, M Girard, P Duquette, P Grammond, R Alroughani, E Pucci, P Sola, R Hupperts, J Lechner-Scott, M Terzi, V Van Pesch, C Rozsa, F Grand'Maison, C Boz, F Granella, M Slee, D Spitaleri, J Olascoaga, R Bergamaschi, F Verheul, S Vucic, P McCombe, S Hodgkinson, JL Sanchez-Menoyo, R Ampapa, M Simo, T Csepany, C Ramo, E Cristiano, M Barnett, H Butzkueven, A Coles, MSBase Study Group

    Alemtuzumab treatment of multiple sclerosis.

    DOI: http://doi.org/10.1055/s-0033-1343797
    Journal: Semin Neurol
    E-pub date: 1 Feb 2013
    Authors: AJ Coles

    Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

    DOI: http://doi.org/10.1212/WNL.0b013e31824e8ee7
    Journal: Neurology
    E-pub date: 3 Apr 2012
    Authors: AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, A Skoromets, I Stolyarov, A Bass, H Sullivan, DH Margolin, SL Lake, S Moran, J Palmer, MS Smith, DAS Compston

    Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

    DOI: http://doi.org/10.1016/S1474-4422(11)70020-5
    Journal: The Lancet Neurology
    E-pub date: 1 Apr 2011
    Authors: AJ Coles, E Fox, A Vladic, SK Gazda, V Brinar, KW Selmaj, AD-D Bass, DR Wynn, DH Margolin, SL Lake, S Moran, J Palmer, MS Smith, DAS Compston

    A novel strategy to reduce the immunogenicity of biological therapies.

    DOI: http://doi.org/10.4049/jimmunol.1000422
    Journal: J Immunol
    E-pub date: 1 Jul 2010
    Authors: J Somerfield, GA Hill-Cawthorne, A Lin, MS Zandi, C McCarthy, JL Jones, M Willcox, D Shaw, SAJ Thompson, AS Compston, G Hale, H Waldmann, AJ Coles

    IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

    DOI: http://doi.org/10.1172/JCI37878
    Journal: J Clin Invest
    E-pub date: 1 Jul 2009
    Authors: JL Jones, C-L Phuah, AL Cox, SA Thompson, M Ban, J Shawcross, A Walton, SJ Sawcer, A Compston, AJ Coles

    Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

    DOI: http://doi.org/10.1056/NEJMoa0802670
    Journal: N Engl J Med
    E-pub date: 23 Oct 2008
    Authors: CAMMS223 Trial Investigators, AJ Coles, DAS Compston, KW Selmaj, SL Lake, S Moran, DH Margolin, K Norris, PK Tandon

    Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

    DOI: http://doi.org/10.1093/brain/119.1.225
    Journal: Brain
    E-pub date: 1 Feb 1996
    Authors: T Moreau, A Coles, M Wing, J Isaacs, G Hale, H Waldmann, A Compston

    Publications

    Chasing MOG antibodies down … assays and lumbar punctures.

    DOI: http://doi.org/10.1093/brain/awad271
    Journal: Brain
    E-pub date: 1 Sep 2023
    Authors: AJ Coles

    Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

    DOI: http://doi.org/10.1101/2023.04.03.23287902
    Journal:
    E-pub date: 1 Aug 2023
    Authors: B Michael, C Dunai, E Needham, K Tharmaratnam, R Williams, Y Huang, S Boardman, J Clark, P Sharma, K Subramaniam, G Wood, C Collie, R Digby, A Ren, E Norton, M Leibowitz, S Ebrahimi, A Fower, H Fox, E Tato, M Ellul, G Sunderland, M Held, C Hetherington, F Nkongho, A Palmos, A Grundmann, J Stewart, M Griffiths, T Solomon, G Breen, A Coles, J Cavanagh, S Irani, A Vincent, L Taams, D Menon

    Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.

    DOI: http://doi.org/10.1177/13524585231151951
    Journal: Mult Scler
    E-pub date: 1 Jun 2023
    Authors: C Daruwalla, V Shaygannejad, S Ozakbas, EK Havrdova, D Horakova, R Alroughani, C Boz, F Patti, M Onofrj, A Lugaresi, S Eichau, M Girard, A Prat, P Duquette, B Yamout, SJ Khoury, SA Sajedi, R Turkoglu, A Altintas, O Skibina, K Buzzard, P Grammond, R Karabudak, A van der Walt, H Butzkueven, D Maimone, J Lechner-Scott, A Soysal, N John, J Prevost, D Spitaleri, C Ramo-Tello, O Gerlach, G Iuliano, M Foschi, R Ampapa, V van Pesch, M Barnett, N Shalaby, M D'hooghe, J Kuhle, MJ Sa, M Fabis-Pedrini, A Kermode, S Mrabet, R Gouider, S Hodgkinson, G Laureys, L Van Hijfte, R Macdonell, C Oreja-Guevara, E Cristiano, P McCombe, JL Sanchez-Menoyo, B Singhal, Y Blanco, S Hughes, J Garber, C Solaro, C McGuigan, B Taylor, K de Gans, M Habek, A Al-Asmi, S Mihaela, T Castillo Triviño, T Al-Harbi, JI Rojas, O Gray, D Khurana, B Van Wijmeersch, N Grigoriadis, J Inshasi, J Oh, E Aguera-Morales, Y Fragoso, F Moore, C Shaw, SM Baghbanian, N Shuey, B Willekens, TA Hardy, D Decoo, AP Sempere, D Field, R Wynford-Thomas, NG Cunniffe, I Roos, CB Malpas, AJ Coles, T Kalincik, JWL Brown

    Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?

    DOI: http://doi.org/10.1136/pn-2022-003531
    Journal: Pract Neurol
    E-pub date: 1 Apr 2023
    Authors: G Brittain, AJ Coles, G Giovannoni, PA Muraro, J Palace, J Petrie, E Roldan, NJ Scolding, JA Snowden, B Sharrack

    The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis.

    DOI: http://doi.org/10.1038/s41380-022-01784-4
    Journal: Mol Psychiatry
    E-pub date: 1 Nov 2022
    Authors: B Lennox, W Xiong, P Waters, A Coles, PB Jones, T Yeo, JTM May, K Yeeles, D Anthony, F Probert

    Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses.

    DOI: http://doi.org/10.1093/brain/awac321
    Journal: Brain
    E-pub date: 6 Sep 2022
    Authors: EJ Needham, AL Ren, RJ Digby, EJ Norton, S Ebrahimi, JG Outtrim, DA Chatfield, AE Manktelow, MM Leibowitz, VFJ Newcombe, R Doffinger, G Barcenas-Morales, C Fonseca, MJ Taussig, RM Burnstein, RJ Samanta, C Dunai, N Sithole, NJ Ashton, H Zetterberg, M Gisslén, A Edén, E Marklund, PJM Openshaw, J Dunning, MJ Griffiths, J Cavanagh, G Breen, SR Irani, A Elmer, N Kingston, C Summers, JR Bradley, LS Taams, BD Michael, ET Bullmore, KGC Smith, PA Lyons, AJ Coles, DK Menon, Cambridge NeuroCOVID Group, CITIID-NIHR COVID-19 BioResource Collaboration, Cambridge NIHR Clinical Research Facility

    Is stem cell transplantation safe and effective in multiple sclerosis?

    DOI: http://doi.org/10.1136/bmj-2020-061514
    Journal: BMJ
    E-pub date: 9 Jun 2022
    Authors: B Sharrack, J Petrie, A Coles, JA Snowden

    Campath, clones and the cause of autoimmunity.

    DOI: http://doi.org/10.1093/brain/awac162
    Journal: Brain
    E-pub date: 3 Jun 2022
    Authors: A Coles

    Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.

    DOI: http://doi.org/10.1177/13524585211046786
    Journal: Mult Scler
    E-pub date: 1 Jun 2022
    Authors: ZG Georgieva, R Dӧffinger, D Kumararatne, AJ Coles, C McCarthy

    Case reports in the Lancet: From neurophobia to global pandemics.

    DOI: http://doi.org/10.1002/ccr3.5693
    Journal: Clin Case Rep
    E-pub date: 1 Apr 2022
    Authors: BO Devoy, PJ Bennett, AJ Coles, HS Mousa

    Susac’s syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.

    DOI: http://doi.org/10.1007/s00415-021-10802-4
    Journal: J Neurol
    E-pub date: 1 Mar 2022
    Authors: A Ahmed, ZQ Kok, A Coles, DJ Scoffings, SJ Crisp

    A method to isolate and cryopreserve cerebrospinal fluid mononuclear cells from external ventricular drains to investigate immunological processes in acute brain injuries.

    DOI: http://doi.org/10.1016/j.jim.2021.113163
    Journal: J Immunol Methods
    E-pub date: 1 Dec 2021
    Authors: RJ Digby, V Coppard, HS Mousa, DK Menon, AJ Coles, JL Jones, EJ Needham

    Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

    DOI: http://doi.org/10.1038/s42003-021-02721-x
    Journal: Commun Biol
    E-pub date: 14 Oct 2021
    Authors: LB Jarvis, DB Rainbow, V Coppard, SK Howlett, Z Georgieva, JL Davies, HK Mullay, J Hester, T Ashmore, A Van Den Bosch, JT Grist, AJ Coles, HS Mousa, S Pluchino, KT Mahbubani, JL Griffin, K Saeb-Parsy, F Issa, L Peruzzotti-Jametti, LS Wicker, JL Jones

    The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK.

    DOI: http://doi.org/10.1016/j.msard.2021.103190
    Journal: Mult Scler Relat Disord
    E-pub date: 1 Oct 2021
    Authors: L Fernandes, CM Allen, T Williams, E Tallantyre, N Evangelou, J Chataway, HL Ford, UK MS Trials and Registries Consortium investigators

    Determinants of therapeutic lag in multiple sclerosis.

    DOI: http://doi.org/10.1177/1352458520981300
    Journal: Multiple Sclerosis Journal
    E-pub date: 1 Oct 2021
    Authors: I Roos, E Leray, F Frascoli, R Casey, JWL Brown, D Horakova, EK Havrdova, M Debouverie, M Trojano, F Patti, G Izquierdo, S Eichau, G Edan, A Prat, M Girard, P Duquette, M Onofrj, A Lugaresi, P Grammond, J Ciron, A Ruet, S Ozakbas, J De Seze, C Louapre, H Zephir, MJ Sá, P Sola, D Ferraro, P Labauge, G Defer, R Bergamaschi, C Lebrun-Frenay, C Boz, E Cartechini, T Moreau, D Laplaud, J Lechner-Scott, F Grand'Maison, O Gerlach, M Terzi, F Granella, R Alroughani, G Iuliano, V Van Pesch, B Van Wijmeersch, DLA Spitaleri, A Soysal, E Berger, J Prevost, E Aguera-Morales, P McCombe, T Castillo Triviño, P Clavelou, J Pelletier, R Turkoglu, B Stankoff, O Gout, E Thouvenot, O Heinzlef, Y Sidhom, R Gouider, T Csepany, B Bourre, A Al Khedr, O Casez, P Cabre, A Montcuquet, A Wahab, J-P Camdessanche, A Maurousset, I Patry, K Hankiewicz, C Pottier, N Maubeuge, C Labeyrie, C Nifle, A Coles, CB Malpas, S Vukusic, H Butzkueven, T Kalincik

    Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.

    DOI: http://doi.org/10.1016/S0140-6736(21)01608-1
    Journal: Lancet
    E-pub date: 25 Sep 2021
    Authors: RJ Perry, A Tamborska, B Singh, B Craven, R Marigold, P Arthur-Farraj, JM Yeo, L Zhang, G Hassan-Smith, M Jones, C Hutchcroft, E Hobson, D Warcel, D White, P Ferdinand, A Webb, T Solomon, M Scully, DJ Werring, C Roffe, CVT After Immunisation Against COVID-19 (CAIAC) collaborators

    Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in England

    DOI: http://doi.org/10.21203/rs.3.rs-1016584/v1
    Journal:
    E-pub date: 1 Aug 2021
    Authors: N Evangelou, A Garjani, S Patel, D Bharkhada, W Rashid, A Coles, G Law

    Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity

    DOI: http://doi.org/10.1101/2021.12.03.21266112
    Journal:
    E-pub date: 1 Aug 2021
    Authors: EJ Needham, AL Ren, RJ Digby, JG Outtrim, DA Chatfield, AE Manktelow, VFJ Newcombe, R Doffinger, G Barcenas-Morales, C Fonseca, MJ Taussig, RM Burnstein, C Dunai, N Sithole, NJ Ashton, H Zetterberg, M Gisslen, A Edén, E Marklund, MJ Griffiths, J Cavanagh, G Breen, SR Irani, A Elmer, N Kingston, JR Bradley, LS Taams, BD Michael, ET Bullmore, KGC Smith, PA Lyons, AJC Coles, DK Menon, the Cambridge NeuroCOVID Group, the NIHR COVID-19 BioResource, Cambridge NIHR Clinical Research Facility

    The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro

    DOI: http://doi.org/10.1101/2021.02.17.431344
    Journal:
    E-pub date: 1 Aug 2021
    Authors: C Gaunt, D Rainbow, R Mackenzie, L Jarvis, H Mousa, N Cunniffe, Z Georgieva, W Brown, A Coles, J Jones

    Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

    DOI: http://doi.org/10.1212/NXI.0000000000001008
    Journal: Neurol Neuroimmunol Neuroinflamm
    E-pub date: 1 Jul 2021
    Authors: OA Abdel-Mannan, C Manchoon, T Rossor, J-C Southin, C Tur, W Brownlee, S Byrne, M Chitre, A Coles, R Forsyth, R Kneen, K Mankad, D Ram, S West, S Wright, E Wassmer, M Lim, O Ciccarelli, C Hemingway, Y Hacohen, UK-Childhood Inflammatory Disease Network

    Neuroanatomical substrates of generalized brain dysfunction in COVID-19.

    DOI: http://doi.org/10.1007/s00134-020-06241-w
    Journal: Intensive Care Med
    E-pub date: 1 Jan 2021
    Authors: VFJ Newcombe, LRB Spindler, T Das, S Winzeck, K Allinson, EA Stamatakis, DK Menon, Cambridge NeuroCovid Imaging Collaborators

    Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.

    DOI: http://doi.org/10.1016/j.cct.2020.106009
    Journal: Contemp Clin Trials
    E-pub date: 31 Aug 2020
    Authors: D Ontaneda, EC Tallantyre, PC Raza, SM Planchon, K Nakamura, D Miller, C Hersh, M Craner, C Bale, B Chaudhry, DD Gunzler, TE Love, S Gerry, A Coles, JA Cohen, N Evangelou

    Parkinson’s disease and spirituality.

    DOI: http://doi.org/10.3233/NRE-192947
    Journal: NeuroRehabilitation
    E-pub date: 1 Aug 2020
    Authors: C Redfern, SL Mason, RA Barker, A Coles

    Therapeutically expanded human regulatory T-cells are super- suppressive due to HIF1A induced expression of CD73.

    DOI: http://doi.org/10.21203/rs.3.rs-92789/v1
    Journal:
    E-pub date: 1 Aug 2020
    Authors: L Jarvis, D Rainbow, V Coppard, S Howlett, J Davies, H Mullay, J Hester, T Ashmore, AVD Bosch, J Grist, A Coles, H Mousa, S Pluchino, K Mahbubani, J Griffin, K Saeb-Parsy, F Issa, L Peruzzotti-Jametti, L Wicker, J Jones

    Hyperpolarized 13C MRI: A novel approach for probing cerebral metabolism in health and neurological disease.

    DOI: http://doi.org/10.1177/0271678X20909045
    Journal: J Cereb Blood Flow Metab
    E-pub date: 1 Jun 2020
    Authors: JT Grist, JJ Miller, F Zaccagna, MA McLean, F Riemer, T Matys, DJ Tyler, C Laustsen, AJ Coles, FA Gallagher

    Neurological Implications of COVID-19 Infections.

    DOI: http://doi.org/10.1007/s12028-020-00978-4
    Journal: Neurocrit Care
    E-pub date: 1 Jun 2020
    Authors: EJ Needham, SH-Y Chou, AJ Coles, DK Menon

    Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

    DOI: http://doi.org/10.1177/1352458518796675
    Journal: Mult Scler
    E-pub date: 1 Oct 2019
    Authors: S Wray, E Havrdova, DR Snydman, DL Arnold, JA Cohen, AJ Coles, H-P Hartung, KW Selmaj, HL Weiner, N Daizadeh, DH Margolin, MC Chirieac, DAS Compston

    Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.

    DOI: http://doi.org/10.1007/s00415-019-09288-y
    Journal: J Neurol
    E-pub date: 1 Jun 2019
    Authors: J Gao, J Jones, EM Damato, A Coles

    Keratinocyte growth factor impairs human thymic recovery from lymphopenia.

    DOI: http://doi.org/10.1172/jci.insight.125377
    Journal: JCI Insight
    E-pub date: 7 May 2019
    Authors: AJ Coles, L Azzopardi, O Kousin-Ezewu, HK Mullay, SA Thompson, L Jarvis, J Davies, S Howlett, D Rainbow, J Babar, TJ Sadler, JWL Brown, E Needham, K May, ZG Georgieva, AE Handel, S Maio, M Deadman, I Rota, G Holländer, S Dawson, D Jayne, R Seggewiss-Bernhardt, DC Douek, JD Isaacs, JL Jones

    Quantifying normal human brain metabolism using hyperpolarized [1-13C]pyruvate and magnetic resonance imaging.

    DOI: http://doi.org/10.1016/j.neuroimage.2019.01.027
    Journal: Neuroimage
    E-pub date: 1 Apr 2019
    Authors: JT Grist, MA McLean, F Riemer, RF Schulte, SS Deen, F Zaccagna, R Woitek, CJ Daniels, JD Kaggie, T Matys, I Patterson, R Slough, AB Gill, A Chhabra, R Eichenberger, M-C Laurent, A Comment, JH Gillard, AJ Coles, DJ Tyler, I Wilkinson, B Basu, DJ Lomas, MJ Graves, KM Brindle, FA Gallagher

    A case of anaphylaxis to alemtuzumab.

    DOI: http://doi.org/10.1007/s00415-019-09214-2
    Journal: J Neurol
    E-pub date: 1 Mar 2019
    Authors: CJS Nye, A Wagner, O Kousin-Ezewu, JL Jones, AJ Coles

    Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment.

    DOI: http://doi.org/10.1111/ene.13759
    Journal: Eur J Neurol
    E-pub date: 1 Nov 2018
    Authors: S Keddie, SJ Crisp, J Blackaby, A Cox, A Coles, M Hart, AJ Church, A Vincent, M Zandi, MP Lunn

    Alemtuzumab as Treatment for Multiple Sclerosis.

    DOI: http://doi.org/10.1101/cshperspect.a032029
    Journal: Cold Spring Harb Perspect Med
    E-pub date: 1 Oct 2018
    Authors: S Katsavos, A Coles

    Women on multiple sclerosis clinical trial steering committees.

    DOI: http://doi.org/10.1002/ana.25306
    Journal: Ann Neurol
    E-pub date: 31 Aug 2018
    Authors: J Moneim, A Coles, G Giovannoni, R Horne, O Carr

    Hemophagocytic Lymphohistiocytosis in 2 Patients with Multiple Sclerosis Treated With Alemtuzumab

    DOI: http://doi.org/10.1212/WNL.0000000000005420
    Journal: Neurology
    E-pub date: 1 May 2018
    Authors: M Saarela, K Senthil, JL Jones, P Tienari, M Soilu-hanninen, L Airas, A Coles, J Saarinen

    Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23Na-MRI.

    DOI: http://doi.org/10.1016/j.jns.2018.01.027
    Journal: J Neurol Sci
    E-pub date: 15 Apr 2018
    Authors: JT Grist, F Riemer, MA McLean, T Matys, F Zaccagna, SF Hilborne, JP Mason, I Patterson, R Slough, J Kaggie, SS Deen, MJ Graves, JL Jones, AJ Coles, FA Gallagher

    Authorship of phase 3 trials in multiple sclerosis.

    DOI: http://doi.org/10.1002/ana.25203
    Journal: Ann Neurol
    E-pub date: 1 Apr 2018
    Authors: A Coles

    Hypothyroid ataxia complicating monoclonal antibody therapy.

    DOI: http://doi.org/10.1136/practneurol-2017-001713
    Journal: Pract Neurol
    E-pub date: 1 Dec 2017
    Authors: A Badran, C Moran, AJ Coles

    A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers.

    DOI: http://doi.org/10.1016/j.jneuroim.2017.08.009
    Journal: J Neuroimmunol
    E-pub date: 15 Nov 2017
    Authors: AM Mori, S Agarwal, MWM Lee, M Rafferty, TA Hardy, A Coles, SW Reddel, DS Riminton

    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

    DOI: http://doi.org/10.1212/WNL.0000000000004354
    Journal: Neurology
    E-pub date: 12 Sep 2017
    Authors: AJ Coles, JA Cohen, EJ Fox, G Giovannoni, H-P Hartung, E Havrdova, S Schippling, KW Selmaj, A Traboulsee, DAS Compston, DH Margolin, K Thangavelu, MC Chirieac, D Jody, P Xenopoulos, RJ Hogan, MA Panzara, DL Arnold, CARE-MS II and CAMMS03409 Investigators

    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

    DOI: http://doi.org/10.1212/WNL.0000000000004313
    Journal: Neurology
    E-pub date: 12 Sep 2017
    Authors: E Havrdova, DL Arnold, JA Cohen, H-P Hartung, EJ Fox, G Giovannoni, S Schippling, KW Selmaj, A Traboulsee, DAS Compston, DH Margolin, K Thangavelu, CE Rodriguez, D Jody, RJ Hogan, P Xenopoulos, MA Panzara, AJ Coles, CARE-MS I and CAMMS03409 Investigators

    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

    DOI: http://doi.org/10.1212/WNL.0000000000003694
    Journal: Neurology
    E-pub date: 7 Mar 2017
    Authors: J Barton, TA Hardy, S Riminton, SW Reddel, Y Barnett, A Coles, MH Barnett

    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

    DOI: http://doi.org/10.1212/WNL.0000000000003319
    Journal: Neurology
    E-pub date: 8 Nov 2016
    Authors: G Giovannoni, JA Cohen, AJ Coles, H-P Hartung, E Havrdova, KW Selmaj, DH Margolin, SL Lake, SM Kaup, MA Panzara, DAS Compston, CARE-MS II Investigators

    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

    DOI: http://doi.org/10.1212/WNL.0000000000003169
    Journal: Neurology
    E-pub date: 4 Oct 2016
    Authors: DL Arnold, E Fisher, VV Brinar, JA Cohen, AJ Coles, G Giovannoni, H-P Hartung, E Havrdova, KW Selmaj, M Stojanovic, HL Weiner, SL Lake, DH Margolin, DR Thomas, MA Panzara, DAS Compston, CARE-MS I and CARE-MS II Investigators

    Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.

    DOI: http://doi.org/10.1007/s00415-015-7925-y
    Journal: JOURNAL OF NEUROLOGY
    E-pub date: 1 Aug 2016
    Authors: L Azzopardi, AL Cox, CL McCarthy, JL Jones, AJ Coles

    Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.

    DOI: http://doi.org/10.1016/j.jns.2016.02.025
    Journal: J Neurol Sci
    E-pub date: 15 Apr 2016
    Authors: EJ Fox, D Wynn, AJ Coles, J Palmer, DH Margolin, CAMMS223 Investigators

    Timing is everything in the treatment of multiple sclerosis.

    DOI: http://doi.org/10.1136/bcr-2014-208960
    Journal: BMJ Case Rep
    E-pub date: 15 Apr 2015
    Authors: CL McCarthy, G Giovannoni, AJ Coles

    Immunotherapy for patients with acute psychosis and serum N-Methyl D-Aspartate receptor (NMDAR) antibodies: a description of a treated case series.

    DOI: http://doi.org/10.1016/j.schres.2014.11.001
    Journal: Schizophr Res
    E-pub date: 1 Dec 2014
    Authors: MS Zandi, JB Deakin, K Morris, C Buckley, L Jacobson, L Scoriels, AL Cox, AJ Coles, PB Jones, A Vincent, BR Lennox

    Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy

    DOI: http://doi.org/10.1016/j.jneuroim.2014.08.167
    Journal: JOURNAL OF NEUROIMMUNOLOGY
    E-pub date: 1 Aug 2014
    Authors: LH Kasper, DL Arnold, AJ Coles, H-P Hartung, E Havrdova, KW Selmaj, J Palmer, DH Margolin, MA Panzara, DAS Compston

    Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

    DOI: http://doi.org/10.1136/jnnp-2013-307042
    Journal: J Neurol Neurosurg Psychiatry
    E-pub date: 1 Jul 2014
    Authors: L Azzopardi, SAJ Thompson, KE Harding, M Cossburn, N Robertson, A Compston, AJ Coles, JL Jones

    Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.

    DOI: http://doi.org/10.1212/WNL.0000000000000520
    Journal: Neurology
    E-pub date: 17 Jun 2014
    Authors: O Kousin-Ezewu, L Azzopardi, RA Parker, O Tuohy, A Compston, A Coles, J Jones

    Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis.

    DOI: http://doi.org/10.1016/j.jneuroim.2014.03.012
    Journal: Journal of Neuroimmunology
    E-pub date: 1 Jan 2014
    Authors: JWL Brown, PJ Martin, JW Thorpe, AW Michell, AJ Coles, AL Cox, A Vincent, MS Zandi

    Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.

    DOI: http://doi.org/10.1073/pnas.1313654110
    Journal: Proc Natl Acad Sci U S A
    E-pub date: 10 Dec 2013
    Authors: JL Jones, SAJ Thompson, P Loh, JL Davies, OC Tuohy, AJ Curry, L Azzopardi, G Hill-Cawthorne, MT Fahey, A Compston, AJ Coles

    First use of alemtuzumab in Balo’s concentric sclerosis: a case report.

    DOI: http://doi.org/10.1177/1352458513498129
    Journal: Mult Scler
    E-pub date: 1 Oct 2013
    Authors: JWL Brown, AJ Coles, JL Jones

    Immune competence after alemtuzumab treatment of multiple sclerosis.

    DOI: http://doi.org/10.1212/WNL.0b013e3182a35215
    Journal: Neurology
    E-pub date: 3 Sep 2013
    Authors: CL McCarthy, O Tuohy, DAS Compston, DS Kumararatne, AJ Coles, JL Jones

    Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

    DOI: http://doi.org/10.2147/DDDT.S32687
    Journal: Drug Des Devel Ther
    E-pub date: 1 Aug 2013
    Authors: JWL Brown, AJ Coles

    Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.

    DOI: http://doi.org/10.1177/1352458512444915
    Journal: Mult Scler
    E-pub date: 1 Feb 2013
    Authors: T Button, D Altmann, D Tozer, C Dalton, K Hunter, A Compston, A Coles, D Miller

    Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

    DOI: http://doi.org/10.1016/S0140-6736(12)61769-3
    Journal: The Lancet
    E-pub date: 1 Nov 2012
    Authors: JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, H-P Hartung, E Havrdova, KW Selmaj, HL Weiner, E Fisher, VV Brinar, G Giovannoni, M Stojanovic, BI Ertik, SL Lake, DH Margolin, MA Panzara, DAS Compston, CARE-MS I investigators

    Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

    DOI: http://doi.org/10.1016/S0140-6736(12)61768-1
    Journal: The Lancet
    E-pub date: 1 Nov 2012
    Authors: AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, H-P Hartung, E Havrdova, KW Selmaj, HL Weiner, T Miller, E Fisher, R Sandbrink, SL Lake, DH Margolin, P Oyuela, MA Panzara, DAS Compston, CARE-MS II investigators

    Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.

    DOI: http://doi.org/10.1212/WNL.0b013e318228bec5
    Journal: Neurology
    E-pub date: 9 Aug 2011
    Authors: M Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, J Zajicek, N Scolding, M Boggild, T Pickersgill, Y Ben-Shlomo, A Coles, NP Robertson

    An evolving case of headaches and strokes.

    DOI: http://doi.org/10.1136/jnnp.2011.242206
    Journal: Pract Neurol
    E-pub date: 1 Apr 2011
    Authors: AJ Shah, DP Breen, D Thomas, J Cross, A Coles, P Molyneux

    Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans.

    DOI: http://doi.org/10.1172/JCI43653
    Journal: J Clin Invest
    E-pub date: 1 Dec 2010
    Authors: E Schoenmakers, M Agostini, C Mitchell, N Schoenmakers, L Papp, O Rajanayagam, R Padidela, L Ceron-Gutierrez, R Doffinger, C Prevosto, J Luan, S Montano, J Lu, M Castanet, N Clemons, M Groeneveld, P Castets, M Karbaschi, S Aitken, A Dixon, J Williams, I Campi, M Blount, H Burton, F Muntoni, D O'Donovan, A Dean, A Warren, C Brierley, D Baguley, P Guicheney, R Fitzgerald, A Coles, H Gaston, P Todd, A Holmgren, KK Khanna, M Cooke, R Semple, D Halsall, N Wareham, J Schwabe, L Grasso, P Beck-Peccoz, A Ogunko, M Dattani, M Gurnell, K Chatterjee

    Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab

    DOI: http://doi.org/10.1016/j.clim.2010.03.310
    Journal: CLINICAL IMMUNOLOGY
    E-pub date: 1 Aug 2010
    Authors: J Jones, A Compston, A Coles